{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAT-8015", "query": { "intervention": "CAT-8015" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAT-8015&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T04:45:16.216Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00659425", "title": "CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "CAT-8015 (Moxetumomab Pasudotox)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 57, "start_date": "2008-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00659425" }, { "nct_id": "NCT01030536", "title": "Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "CAT-8015 20 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 30 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 40 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 50 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 60 mcg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 23, "start_date": "2010-02-15", "completion_date": "2013-03-04", "has_results": true, "last_update_posted_date": "2018-04-09", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 7, "location_summary": "Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030536" }, { "nct_id": "NCT00515892", "title": "Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Non-Hodgkin's Lymphoma", "NHL" ], "interventions": [ { "name": "Immunotoxin therapy", "type": "DRUG" }, { "name": "CAT-8015 Immunotoxin", "type": "DRUG" }, { "name": "Biological therapy", "type": "PROCEDURE" }, { "name": "Antibody Therapy", "type": "PROCEDURE" }, { "name": "Monoclonal Antibody Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Cambridge Antibody Technology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2007-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-08-14", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 2, "location_summary": "Beverly Hills, California • Bethesda, Maryland", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00515892" }, { "nct_id": "NCT00586924", "title": "A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hairy Cell Leukemia" ], "interventions": [ { "name": "Moxetumomab Pasudotox (CAT 8015)", "type": "DRUG" }, { "name": "CAT 8015 (Moxetumomab Pasudotox)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 49, "start_date": "2007-05-10", "completion_date": "2015-05-06", "has_results": true, "last_update_posted_date": "2019-04-02", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 3, "location_summary": "Stanford, California • Chicago, Illinois • Bethesda, Maryland", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586924" }, { "nct_id": "NCT00587015", "title": "A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "CAT-8015", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 50, "start_date": "2007-08", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2011-11-22", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 2, "location_summary": "Beverly Hills, California • Bethesda, Maryland", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00587015" }, { "nct_id": "NCT02338050", "title": "Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)" ], "interventions": [ { "name": "Moxetumomab Pasudotox", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "24 Years", "sex": "ALL", "summary": "6 Months to 24 Years" }, "enrollment_count": 1, "start_date": "2015-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-09-16", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02338050" }, { "nct_id": "NCT00462189", "title": "Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Hairy Cell Leukemia", "HCL" ], "interventions": [ { "name": "Immunotoxin therapy", "type": "DRUG" }, { "name": "CAT-8015 Immunotoxin", "type": "DRUG" }, { "name": "Biological therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Cambridge Antibody Technology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-04-18", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 3, "location_summary": "Stanford, California • Chicago, Illinois • Bethesda, Maryland", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462189" }, { "nct_id": "NCT04125290", "title": "US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hairy Cell Leukemia" ], "interventions": [], "intervention_types": [], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2, "start_date": "2019-12-09", "completion_date": "2021-06-21", "has_results": false, "last_update_posted_date": "2025-07-18", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 2, "location_summary": "Pueblo, Colorado • Bridgeton, Missouri", "locations": [ { "city": "Pueblo", "state": "Colorado" }, { "city": "Bridgeton", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04125290" }, { "nct_id": "NCT03805932", "title": "Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hairy Cell Leukemia" ], "interventions": [ { "name": "Moxetumomab Pasudotox-tdfk", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Ruxience", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-10-03", "completion_date": "2029-06-30", "has_results": true, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03805932" }, { "nct_id": "NCT00587457", "title": "A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphoma, Chronic Lymphocytic", "Leukemia, Prolymphocytic Leukemia, Small", "Lymphocytic Lymphoma, Moxetumomab Pasudotox" ], "interventions": [ { "name": "CAT-8015 5 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 10 mcg/kg", "type": "DRUG" }, { "name": "CAT-8015 20 mcg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2007-03-07", "completion_date": "2008-04-07", "has_results": true, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-09-13T04:45:16.216Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Bethesda, Maryland", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00587457" } ] }